Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC.

Decker WK, Shah N, Xing D, Lapushin R, Li S, Robinson SN, Yang H, Parmar S, Halpert MM, Keating MJ, Gribben JG, Molldrem JJ, Shpall EJ, Wierda WG.

PLoS One. 2012;7(12):e51390. doi: 10.1371/journal.pone.0051390. Epub 2012 Dec 19.

2.

HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: implications for disease control by physiological immune surveillance.

Shah N, Decker WK, Lapushin R, Xing D, Robinson SN, Yang H, Parmar S, Tung SS, O'Brien S, Fernandez-Viña M, Shpall EJ, Wierda WG.

Leukemia. 2011 Jun;25(6):1036-9. doi: 10.1038/leu.2011.30. Epub 2011 Feb 25. No abstract available.

PMID:
21350559
3.

CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia.

Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA.

Blood. 2011 Feb 3;117(5):1662-9. doi: 10.1182/blood-2010-09-307249. Epub 2010 Nov 29.

4.

Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.

Ferrajoli A, Wierda WG, LaPushin R, O'Brien SM, Faderl S, Browning ML, Keating MJ.

Eur J Haematol. 2008 Apr;80(4):296-8. doi: 10.1111/j.1600-0609.2007.01023.x. Epub 2007 Dec 21.

PMID:
18182081
5.

Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase.

Liu S, Yu S, Hasegawa Y, Lapushin R, Xu HJ, Woodgett JR, Mills GB, Fang X.

J Biol Chem. 2004 Dec 3;279(49):51075-81. Epub 2004 Oct 1.

6.

Lysophosphatidic acid production and action: validated targets in cancer?

Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, Hasegawa Y, Lu Y, Trost R, Bevers T, Jonasch E, Aldape K, Liu J, James RD, Ferguson CG, Xu Y, Prestwich GD, Mills GB.

J Cell Biochem. 2004 Aug 15;92(6):1115-40. Review. Erratum in: J Cell Biochem. 2004 Oct 1;93(2):427.

PMID:
15258897
7.

Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells.

Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB.

J Biol Chem. 2004 Mar 5;279(10):9653-61. Epub 2003 Dec 11.

8.

Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.

Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, Lu K, Smith DI, Kalli K, Hartmann LC, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, Yamal JM, Bast RC, Felix EA, Newman RA, Mills GB.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3534-45.

9.

Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival.

Lee HY, Srinivas H, Xia D, Lu Y, Superty R, LaPushin R, Gomez-Manzano C, Gal AM, Walsh GL, Force T, Ueki K, Mills GB, Kurie JM.

J Biol Chem. 2003 Jun 27;278(26):23630-8. Epub 2003 Apr 24.

10.

The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition.

Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, Bast RC Jr.

J Biol Chem. 2003 Jun 27;278(26):23441-50. Epub 2003 Apr 16.

11.

The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.

Tanyi JL, Morris AJ, Wolf JK, Fang X, Hasegawa Y, Lapushin R, Auersperg N, Sigal YJ, Newman RA, Felix EA, Atkinson EN, Mills GB.

Cancer Res. 2003 Mar 1;63(5):1073-82.

12.

Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway.

Bao JJ, Le XF, Wang RY, Yuan J, Wang L, Atkinson EN, LaPushin R, Andreeff M, Fang B, Yu Y, Bast RC Jr.

Cancer Res. 2002 Dec 15;62(24):7264-72.

13.

Lysophosphatidic acid is a bioactive mediator in ovarian cancer.

Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J, Mills GB.

Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64. Review.

PMID:
12069836
14.

Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells.

Tanyi JL, Lapushin R, Eder A, Auersperg N, Tabassam FH, Roth JA, Gu J, Fang B, Mills GB, Wolf J.

Gynecol Oncol. 2002 Jun;85(3):451-8.

PMID:
12051873
15.

Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer.

Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam FH, Wiener J, Lapushin R, Yu S, Parrott JA, Compton T, Tribley W, Fishman D, Stack MS, Gaudette D, Jaffe R, Furui T, Aoki J, Erickson JR.

Cancer Treat Res. 2002;107:259-83. Review.

PMID:
11775454
16.

In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299.

Ho L, Aytac U, Stephens LC, Ohnuma K, Mills GB, McKee KS, Neumann C, LaPushin R, Cabanillas F, Abbruzzese JL, Morimoto C, Dang NH.

Clin Cancer Res. 2001 Jul;7(7):2031-40.

17.

Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase.

Cuevas BD, Lu Y, Mao M, Zhang J, LaPushin R, Siminovitch K, Mills GB.

J Biol Chem. 2001 Jul 20;276(29):27455-61. Epub 2001 May 3.

18.
19.

Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase.

Fang X, Yu S, LaPushin R, Lu Y, Furui T, Penn LZ, Stokoe D, Erickson JR, Bast RC Jr, Mills GB.

Biochem J. 2000 Nov 15;352 Pt 1:135-43.

20.

Insulin-like growth factor binding protein-6 inhibits the growth of human bronchial epithelial cells and increases in abundance with all-trans-retinoic acid treatment.

Sueoka N, Lee HY, Walsh GL, Fang B, Ji L, Roth JA, LaPushin R, Hong WK, Cohen P, Kurie JM.

Am J Respir Cell Mol Biol. 2000 Sep;23(3):297-303.

PMID:
10970819
21.

Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer.

Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, Pustilnik T, Sasagawa T, Lapushin R, Yu S, Jaffe RB, Wiener JR, Erickson JR, Mills GB.

Ann N Y Acad Sci. 2000 Apr;905:188-208. Review.

PMID:
10818454
22.

Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner.

Furui T, LaPushin R, Mao M, Khan H, Watt SR, Watt MA, Lu Y, Fang X, Tsutsui S, Siddik ZH, Bast RC, Mills GB.

Clin Cancer Res. 1999 Dec;5(12):4308-18.

23.

The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells.

Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, Davies MA, Khan H, Furui T, Mao M, Zinner R, Hung MC, Steck P, Siminovitch K, Mills GB.

Oncogene. 1999 Nov 25;18(50):7034-45.

24.

Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis.

Davies MA, Lu Y, Sano T, Fang X, Tang P, LaPushin R, Koul D, Bookstein R, Stokoe D, Yung WK, Mills GB, Steck PA.

Cancer Res. 1998 Dec 1;58(23):5285-90. Erratum in: Cancer Res 1999 Mar 1;59(5):1167.

26.

p202 prevents apoptosis in murine AKR-2B fibroblasts.

Koul D, Lapushin R, Xu HJ, Mills GB, Gutterman JU, Choubey D.

Biochem Biophys Res Commun. 1998 Jun 18;247(2):379-82.

PMID:
9642135
27.
28.

Molecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with an autocrine response to GM-CSF.

Estrov Z, Talpaz M, Ku S, Harris D, LaPushin R, Koller CA, Hirsh-Ginsberg C, Huh Y, Yee G, Kurzrock R.

Leukemia. 1996 Sep;10(9):1534-43.

PMID:
8751477
29.

Qualitative and quantitative differences in the cellular responses mediated through Fas antigen and tumor necrosis factor receptor.

Totpal K, Singh S, Lapushin R, Aggarwal BB.

J Interferon Cytokine Res. 1996 Mar;16(3):259-67.

PMID:
8697149
30.

Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation.

Estrov Z, Black RA, Sleath PR, Harris D, Van Q, LaPushin R, Estey EH, Talpaz M.

Blood. 1995 Dec 15;86(12):4594-602.

PMID:
8541550
31.

Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation.

Estrov Z, Samal B, Lapushin R, Kellokumpu-Lehtinen P, Sahin AA, Kurzrock R, Talpaz M, Aggarwal BB.

J Interferon Cytokine Res. 1995 Oct;15(10):905-13.

PMID:
8564713
32.

Retinoids downregulate both p60 and p80 forms of tumor necrosis factor receptors in human histiocytic lymphoma U-937 cells.

Totpal K, Chaturvedi MM, LaPushin R, Aggarwal BB.

Blood. 1995 Jun 15;85(12):3547-55.

PMID:
7780141
34.
35.

TNF and its receptor antibody agonist differ in mediation of cellular responses.

Totpal K, LaPushin R, Kohno T, Darnay BG, Aggarwal BB.

J Immunol. 1994 Sep 1;153(5):2248-57.

PMID:
8051422
36.
37.
38.

Tumor necrosis factor alpha and gamma-interferon enhancement of anti-epidermal growth factor receptor monoclonal antibody binding to human melanoma cells.

Mujoo K, Donato NJ, Lapushin R, Rosenblum MG, Murray JL.

J Immunother Emphasis Tumor Immunol. 1993 Apr;13(3):166-74.

PMID:
8471591
39.

In vitro selection of NIH-3T3 cells for resistance to lymphotoxin induces resistance to activated macrophages and enhances tumorigenicity in vivo.

Totpal K, Lapushin R, Ananthaswamy HN, Aggarwal BB.

Lymphokine Cytokine Res. 1991 Oct;10(5):359-67.

PMID:
1768739
40.
41.

Synergism between alpha-interferon and interleukin-2-activated killer cells: in vitro studies.

Di Raimondo F, LaPushin R, Hersh EM.

Acta Haematol. 1987;78 Suppl 1:77-83.

PMID:
3124452
42.

Impaired in vitro interferon, blastogenic, and natural killer cell responses to viral stimulation in acquired immune deficiency syndrome.

Hersh EM, Gutterman JU, Spector S, Friedman H, Greenberg SB, Reuben JM, LaPushin R, Matza M, Mansell PW.

Cancer Res. 1985 Jan;45(1):406-10.

43.

Suppressor cell activity among the peripheral blood leukocytes of selected homosexual subjects.

Hersh EM, Mansell PW, Reuben JM, Frank J, Rios A, LaPushin R, Newell G.

Cancer Res. 1983 Apr;43(4):1905-9. No abstract available.

44.

Ultrastructural study of satellite lymph nodes in syphilitic rabbits.

Lapushin RW, Baughn RE, Musher DM, Gyorkey P.

Br J Vener Dis. 1979 Jun;55(3):168-72.

45.

The role of a vaccine for syphilis.

Musher DM, Baughn RE, Lapushin RW, Knox JM, Duncan WC.

Sex Transm Dis. 1977 Oct-Dec;4(4):163-6. No abstract available.

PMID:
339377

Supplemental Content

Loading ...
Support Center